LNCap clone FGC
LNCap clone FGC
Cell Line Name
Cell Line Description
Derived from a metastasis at the left supraclavicular lymph node of a 50 year old patient with a confirmed diagnosis of metastatic prostate carcinoma. Growth and acid phosphatase production is affected by 5-alpha-dihydrotestosterone. They do not form a uniform monolayer and attach only lightly to the substrate. When shipped, cells detach from flask and can either be incubated 24-48 hours to allow attachment or be collected by centrifugation (150xg, 15 minutes) and reseeded.
General Info
Species
Human
Other Collection No.
Links
Cellosaurus: CVCL_1379
Release Conditions
Characteristics
Receptors
Products
Tissue of Origin
DNA profile (STR Profile)
Amelogenin: X,Y
CSF1PO: 10,11
D5S818: 11,12
D7S820: 9,11
D13S317: 10,12
D16S539: 11
TH01: 9
TPOX: 8,9
vWA: 16,18
Karyotype
Disease
Culture Conditions
Cell Type
Subculture Routine
Split sub-confluent cultures (70-80%) 1:3 to 1:6 using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C.i.e. seeding at 3-4 x 10,000 cells/cm² Cells grow slowly in clusters and can be disaggregated by repeated pipetting. After subculture cells may take up to 48 hours to reattach. Do not disturb during this period. Medium is rapidly acidified, therefore change twice per week.
Culture Medium
RPMI 1640 + 2mM Glutamine + 1.0 mM sodium pyruvate + 10% Foetal Bovine Serum (FBS).
Growth Mode
Additional Info
Depositor
Country of Origin
Hazard Group (ACDP)
Applications
References
Cancer Genet Cytogenet 1984; 11:399; Cancer Res 1983; 43:1809; Cancer Res 1997; 57:3339; J Biol Chem 1996; 271:13228
Bibliography
Murphy, G.P.,ed.,Models for prostate cancer.37 New York:Liss;1980:pp115-132 Gibas Z et al. A high resolution study of chromosome changes in a human prostatic carcinoma cell line (LNCap).Cancer Genet. Cytogenet. 11:399-404,1984 Horoszewicz JS et al. LNCap model of human prostatic carcinoma. Cancer Res. 43:1809-1818, 1983 Hu SX et al. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Re. 57:3339-3343,1997 Boffa LC et al. Invasion of the CAG triplet repeats by a complementary peptide nucleic acid inhibits transcription of the androgen receptor and TATA-binding protein genes and correlates with refolding of an active nucleosome containing a unique AR gene sequence. J.Biol. Chem. 271:13228-13233, 1996
Documents
Images
Available Formats
- Frozen
- DNA-5µg (100ng/µl)
Citation Guidance
If use of this culture results in a scientific publication, it should be cited in the publication as: LNCap clone FGC (ECACC 89110211).
Biosafety Information
Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Further Information
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.